Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRXNASDAQ:HAPPNASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsHAPPHappiness Development Group$1.35$1.37$2.08▼$7.40$9.39M0.2314,340 shs16,400 shsSLNOSoleno Therapeutics$69.64+3.2%$51.64$36.61▼$74.00$3.19B-2.29673,443 shs1.62 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HAPPHappiness Development Group0.00%0.00%-4.93%+5.46%-20.12%SLNOSoleno Therapeutics+3.20%-2.53%+55.52%+50.67%+66.60%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHAPPHappiness Development GroupN/AN/AN/AN/AN/AN/AN/AN/ASLNOSoleno Therapeutics4.4826 of 5 stars4.61.00.04.63.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/AHAPPHappiness Development Group 0.00N/AN/AN/ASLNOSoleno Therapeutics 3.22Buy$99.6343.06% UpsideCurrent Analyst Ratings BreakdownLatest ACRX, HAPP, and SLNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $100.003/28/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $81.003/28/2025SLNOSoleno TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $108.003/27/2025SLNOSoleno TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$105.003/27/2025SLNOSoleno TherapeuticsLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $105.003/27/2025SLNOSoleno TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $123.003/27/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $102.003/5/2025SLNOSoleno TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$74.003/3/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/4/2025SLNOSoleno TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00HAPPHappiness Development Group$95.59M0.10N/AN/A$19.57 per share0.07SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/AHAPPHappiness Development Group-$49.19M$0.482.81∞N/AN/AN/AN/AN/ASLNOSoleno Therapeutics-$38.99M-$4.26N/AN/AN/AN/A-61.99%-55.21%5/8/2025 (Estimated)Latest ACRX, HAPP, and SLNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/2025Q4 2024SLNOSoleno Therapeutics-$0.86-$1.27-$0.41-$1.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AHAPPHappiness Development GroupN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04HAPPHappiness Development GroupN/A2.011.94SLNOSoleno TherapeuticsN/A17.2617.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%HAPPHappiness Development Group15.22%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%HAPPHappiness Development Group15.58%SLNOSoleno Therapeutics12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableHAPPHappiness Development Group2156.96 million5.87 millionNot OptionableSLNOSoleno Therapeutics3045.86 million37.81 millionOptionableACRX, HAPP, and SLNO HeadlinesRecent News About These CompaniesAtika Capital Management LLC Takes Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)April 8 at 5:56 AM | marketbeat.comWellington Management Group LLP Has $35.16 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)April 8 at 4:05 AM | marketbeat.comCinctive Capital Management LP Invests $594,000 in Soleno Therapeutics, Inc. (NASDAQ:SLNO)April 6 at 5:14 AM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - Time to Buy?April 5 at 6:41 PM | marketbeat.comQ1 EPS Estimate for Soleno Therapeutics Lifted by AnalystApril 5 at 7:37 AM | marketbeat.comBryce Point Capital LLC Purchases New Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)April 5 at 5:39 AM | marketbeat.comPatricia C. Hirano Sells 3,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockApril 4, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for SLNO EarningsApril 4, 2025 | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Shares Down 6.7% After Insider SellingApril 3, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $265,156.02 in StockApril 3, 2025 | insidertrades.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Down 6.7% on Insider SellingApril 3, 2025 | americanbankingnews.comWinners and wishers: 8 potential Bay Area drug approvals coming this yearApril 2, 2025 | bizjournals.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, HC Wainwright Analyst SaysApril 2, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 SharesApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) VP Sells $1,013,664.33 in StockApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 90,622 SharesApril 1, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 128,653 Shares of StockApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 SharesApril 1, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume After Analyst UpgradeApril 1, 2025 | marketbeat.comSoleno Therapeutics price target raised to $100 from $70 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $100.00April 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesGold Rally vs. Oil Surge: Where Investors Are Betting NextBy Gabriel Osorio-Mazilli | March 13, 2025View Gold Rally vs. Oil Surge: Where Investors Are Betting NextBoeing Breaks Out: What the Market Is Signaling NowBy Gabriel Osorio-Mazilli | March 25, 2025View Boeing Breaks Out: What the Market Is Signaling NowPowell Warns of More Inflation—Here’s Where Smart Money Is MovingBy Gabriel Osorio-Mazilli | March 24, 2025View Powell Warns of More Inflation—Here’s Where Smart Money Is MovingU.S. Steel and Nippon Merger: Should Investors Bet on It?By Jea Yu | March 31, 2025View U.S. Steel and Nippon Merger: Should Investors Bet on It?Meta Eyes India: Breaking Down Its Quest for Reliance PartnershipBy Leo Miller | April 7, 2025View Meta Eyes India: Breaking Down Its Quest for Reliance PartnershipACRX, HAPP, and SLNO Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Happiness Development Group NASDAQ:HAPP$1.35 0.00 (0.00%) As of 04/4/2025Happiness Development Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures. In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. The company was formerly known as Happiness Biotech Group Limited and changed its name to Happiness Development Group Limited in October 2022. Happiness Development Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.Soleno Therapeutics NASDAQ:SLNO$69.64 +2.16 (+3.20%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$69.97 +0.33 (+0.48%) As of 08:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
